Crick — Clinical Intelligence Platform

Not applicableStudy completedNCT01505205

What this trial is testing

Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors

Who this might be right for

Full Gene Sequences of c-KIT、PDGFRA and DOG1 Are Analyzed With the Screening-sequencing ApproachInvestigate the Characteristics and Variations Associated With the Different Gene Mutations of c-KIT、PDGFRA and DOG1 in GIST Patients

Guangxi Medical University 60

Results for “KIT Gene Mutation”

Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation

Imatinib Dose Escalation to 800 mg/Day in Korean Patients With Metastatic or Unresectable GIST Harboring KIT Exon 9 Mutation: KENEDI

A New Treatment of Newly Diagnosed KIT Mutation CBF-Acute Myeloid Leukemia

Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor

Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

A Retrospective Study of C-kit Mutation Status in Asian Patients With Advanced Gastro-intestinal Stromal Tumors (GIST) Treated With Imatinib.

Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Study on the Evolution of Genes Mutation Related With Gastrointestinal Stromal Tumors

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany